ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bimagrumab

Also written as “Bimagrumab”, “BYM338” and “LY3985863”.

Its studies are mostly in Myositis, Inclusion Body · Obesity · Sarcopenia · Cachexia · Heart Failure, Diastolic, led by 2 companies.

Drug pageBimagrumab: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 15, 201318 company-led studies, 1 open or runningAcquisition: Lilly acquired Versanis Bio, Aug 2023Next primary completion: Jul 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis120 open or runningphase 3since Aug 15, 2013Aug 12, 2011none ahead
Eli Lillyits history only61 open or runningphase 2since Oct 16, 2022Oct 16, 2022Jul 2029phase 2 · NCT07920887
  • Named in Eli Lilly’s own pipeline as Bimagrumab, phase 2, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Versanis Bio.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

How Novartis relates to it is not in the registry or these sources.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2011First studies: 2 phase 2 studiesFirst studyNCT01423110, NCT01433263
  2. Feb 17, 2012Phase 2 study in Skeletal MuscleNCT01601600 · 40 enrolled · United States
  3. Mar 1, 2012Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT01669174 · 67 enrolled · United States, Netherlands, United Kingdom
  4. Apr 12, 2013Phase 2 study in CachexiaNCT01868685
  5. Aug 15, 2013Phase 3 study in Myositis, Inclusion BodyNCT01925209 · 251 enrolled · United States, Australia, Belgium and more
  6. Mar 20, 2014Phase 3 study in Myositis, Inclusion BodyNCT02250443 · 10 enrolled · United States
  7. May 8, 2014Phase 2 study in Muscular AtrophyNCT02152761 · 251 enrolled · United States, Argentina, Australia and more
  8. Dec 10, 2014Phase 2 study in SarcopeniaNCT02333331 · 217 enrolled · United States, Australia, Belgium and more
  9. Apr 30, 2015Phase 2 study in SarcopeniaNCT02468674 · 160 enrolled · United States, Australia, Belgium and more
  10. Jul 9, 2015Phase 3 study in Myositis, Inclusion BodyNCT02573467 · 211 enrolled · United States, Australia, Belgium and more
  11. Dec 24, 2016Phase 2 study in Diabetes Mellitus, Type 2NCT03005288 · 78 enrolled · United States, United Kingdom
  12. Aug 14, 2023Lilly acquired Versanis BioAcquisitionWith it bimagrumab, its lead asset · completed · Lilly (release)

TargetBeta

“A human monoclonal antibody directed against type II activin receptors (ActRII; ActR2), with potential muscle-sparing and anti-cachectic activities. Upon administration, bimagrumab binds to ActRII, which prevents the binding of the natural ligands, myostatin and activin, to activin receptors and …”NCIt, read by Claude
“Activin receptor type-2B antagonist”ChEMBL 37, by rule

Studies

All 12 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03005288Diabetes Mellitus, Type 2 · United States, United Kingdom2CompletedMar 21, 201978
NCT02573467Myositis, Inclusion Body · United States, Australia, Belgium and more3CompletedAug 17, 2016211
NCT02468674Sarcopenia · United States, Australia, Belgium and more2CompletedDec 3, 2018160
NCT02333331Sarcopenia · United States, Australia, Belgium and more2CompletedJun 26, 2018217
NCT02152761Muscular Atrophy · United States, Argentina, Australia and more2CompletedMay 14, 2018251
NCT02250443Myositis, Inclusion Body · United States3CompletedAug 23, 201610
NCT01925209Myositis, Inclusion Body · United States, Australia, Belgium and more3CompletedJan 6, 2016251
NCT01868685Cachexia2WithdrawnJan 20150
NCT01669174Pulmonary Disease, Chronic Obstructive · United States, Netherlands, United Kingdom2CompletedDec 201467
NCT01601600Skeletal Muscle · United States2CompletedDec 201340
NCT01433263Cachexia · United States, Lithuania, Romania and more2CompletedApr 201457
NCT01423110Myositis, Inclusion Body · United States2CompletedMay 201214

How it is read

Names in the registry

  • “Bimagrumab”, 6 entries
  • “BYM338”, 4 entries
  • “bimagrumab”, 3 entries
  • “LY3985863”, 1 entry
  • “BYM338 10 mg/kg”, 1 entry

Codes read as this program: LY3985863.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.